These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
117 related items for PubMed ID: 12213472
1. Quantitative structure-activity relationship studies on 5-phenyl-3-ureido-1,5-benzodiazepine as cholecystokinin-A receptor antagonists. Agrawal VK, Sharma R, Khadikar PV. Bioorg Med Chem; 2002 Nov; 10(11):3571-81. PubMed ID: 12213472 [Abstract] [Full Text] [Related]
2. Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists. Ursini A, Capelli AM, Carr RA, Cassarà P, Corsi M, Curcuruto O, Curotto G, Dal Cin M, Davalli S, Donati D, Feriani A, Finch H, Finizia G, Gaviraghi G, Marien M, Pentassuglia G, Polinelli S, Ratti E, Reggiani AM, Tarzia G, Tedesco G, Tranquillini ME, Trist DG, Van Amsterdam FT. J Med Chem; 2000 Oct 05; 43(20):3596-613. PubMed ID: 11020274 [Abstract] [Full Text] [Related]
4. Potent and subtype-selective CCK-B/gastrin receptor antagonists: 2,4-dioxo-1,5-benzodiazepines with a plane of symmetry. Hagishita S, Seno K, Kamata S, Haga N, Ishihara Y, Ishikawa M, Shimamura M. Bioorg Med Chem; 1997 Jul 05; 5(7):1433-46. PubMed ID: 9377103 [Abstract] [Full Text] [Related]
5. Quantitative structure-activity relationship study on some nonpeptidal cholecystokinin antagonists. Sinha J, Kurup A, Paleti A, Gupta SP. Bioorg Med Chem; 1999 Jun 05; 7(6):1127-30. PubMed ID: 10428383 [Abstract] [Full Text] [Related]
9. Benzodiazepine ligands can act as allosteric modulators of the Type 1 cholecystokinin receptor. Gao F, Sexton PM, Christopoulos A, Miller LJ. Bioorg Med Chem Lett; 2008 Aug 01; 18(15):4401-4. PubMed ID: 18621527 [Abstract] [Full Text] [Related]
13. Synthesis and evaluation of 1,5-benzodiazepines with bridged cycloalkyl substituents at the N-1 position as potent and selective CCK-B Ligands. Finizia G, Donati D, Pentassuglia G, Polinelli S, Tarzia G, Tranquillini ME, Ursini A. Arch Pharm (Weinheim); 1998 Jan 01; 331(1):41-4. PubMed ID: 9507701 [Abstract] [Full Text] [Related]
17. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. Evans BE, Rittle KE, Bock MG, DiPardo RM, Freidinger RM, Whitter WL, Lundell GF, Veber DF, Anderson PS, Chang RS. J Med Chem; 1988 Dec 01; 31(12):2235-46. PubMed ID: 2848124 [Abstract] [Full Text] [Related]
18. Synthesis and structure-activity relationships of dual histamine H2 and gastrin receptor antagonists with noncyclic gastrin receptor antagonistic moieties. Kawanishi Y, Ishihara S, Kiyama R, Hagishita S, Tsushima T, Ishikawa M, Ishihara Y. Bioorg Med Chem; 1997 Jul 01; 5(7):1425-31. PubMed ID: 9377102 [Abstract] [Full Text] [Related]
19. A second generation of non-peptide cholecystokinin receptor antagonists and their possible therapeutic potential. Freedman SB, Patel S, Smith AJ, Chapman K, Fletcher A, Kemp JA, Marshall GR, Hargreaves RJ, Scholey K, Mellin EC. Ann N Y Acad Sci; 1994 Mar 23; 713():312-8. PubMed ID: 8185173 [Abstract] [Full Text] [Related]